Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene

Radiation Oncology Investigations

Volumn 7, Issue 4, 1999, Pages 204-217

  Stickle, Robert L ^a   Epperly, Michael W ^a   Klein, Edwin ^a   Bray, Jenifer A ^a   Greenberger, Joel S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Gene therapy; Ionizing radiation; MnSOD

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGITIS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION HAZARD; RADIATION INJURY; TRANSGENE;

ANIMALS; DNA; DNA PRIMERS; DRUG DELIVERY SYSTEMS; ESOPHAGITIS; ESOPHAGUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; LIPOSOMES; MALE; MICE; MICE, INBRED C3H; PLASMIDS; POLYMERASE CHAIN REACTION; RADIATION INJURIES, EXPERIMENTAL; SUPEROXIDE DISMUTASE; TRANSGENES;

EID: 0032888334     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:4<204::AID-ROI2>3.0.CO;2-S     Document Type: Article

References (40)

1. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323(14):940-945.
2. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, Ruffle P, Martin M, Douillard JY. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84(1):58.
3. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83(6):417-423.
4. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87(3):198-205.
5. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen JH, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326(8):524-530.
6. Choy H, Akerley WL, DeVore R. Paclitaxel in combined-modality therapy for locally advanced non-small cell lung cancer. Adv Oncol 1993;13(4):17-24.
7. Choi NC, Herdon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528-3536.
8. Mehata MP, Tannehill SP, Adak S, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998; 16:3518-3523.
9. Mirimanoff RO, Moro D, Bolla M, Michel IG, Brambilla C, Mermillod B, Miralbell R, Alberto P. Alternating radiotherapy and chemotherapy for inoperable stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Int J Radiat Oncol Biol Phys 1998;42:487-494.
10. Byhardt RW, Scott C, Sause WT, Emami B, Komake R, Fisher B, Lee JS, Lawton C. Response, toxicity, failure patterns, and survival in five radiation therapy oncology groups (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell lung carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-478.
11. Chen LM, Ignacio L, Jacobs R, Kozloff M, Telfer M, Elahi R, Evans R, Vijayakumar S. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer. Radiat Oncol Invest 1999;7:49-53.
12. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin MB, Kasper DL, Hauser SL, Long DL. Harrison's principles of internal medicine 14th ed., vol. 2. New York: McGraw-Hill; 1991. p 1594-1595.
13. Phillips TL, Margolis L. Radiation pathology and the clinical response of lung and esophagus. In: Vaeth JM, editor. Frontiers of radiation therapy and oncology, vol. 6. Basel: S Karger; 1961. p 254-273.
14. Rubin P, Casarett, GW. In: Clinical radiation pathology, vol. 1. Philadelphia: W.B. Saunders; 1968. p 156-159; 423-470.
15. Jennings F, Arden A. Development of experimental radiation pneumonitis. Arch Pathol 1961;71:437-446.
16. Segawa Y, Takigawa N, Kataoka M, Takata I, Fujimoto N, Ueoka H. Risk factors for development of radiation pneumonitis after radiation therapy with or without chemotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1997;39(1):91-98.
17. Sherman DM, Carabell SC, Belli JA, Hellman S. The effect of dose rate and adriamycin on the tolerance of thoracic radiation in mice. Int J Radiat Oncol Biol Phys 1982;8(1):45-51.
18. Berthrong M. Pathologic changes secondary to radiation. World J Surg 1986;10(2):155-170.
19. Jennings F, Arden A. Acute radiation effects in the esophagus. Arch Pathol 1960;69:407-412.
20. Mascarenhas F, Silvestre ME, Sa da Costa M, Grima N, Campos C, Chaves P. Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung. Am J Clin Oncol 1989;12(1):34-40.
21. Phillips TL, Ross G. Time-dose relationships in the mouse esophagus. Radiology 1974;113(2):435-440.
22. Arriagada R, Le Chevalier T. Combined modalities in small-cell lung cancer In: Johnson BE, Johnson DH, editors. Lung cancer. New York: Wiley-Liss; 1995. p 263-280.
23. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982;9(1):34-51.
24. Phillips TL, Margolis L. Radiation pathology and the clinical response of lung and esophagus. In: Vaeth JM, editor. Frontiers of radiation therapy and oncology, vol. 6. Basel: S. Karger; 1961. p 254-273.
25. Roach M, Gandara DR, Yuo H, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L, Phillips TL. Radiation pneumonitis after combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995;13(10):2606-2612.
26. Choy H, Aderley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced nonsmall-cell lung cancer. J Clin Oncol 1998;16:3316-3322.
27. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16(1):159-164.
28. Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 1993;85(17):1382-1397.
29. Northway MG, Eastwood GL, Libshitz HI, Feldman MS, Mamel JJ, Szwarc IA. Anti-inflammatory agents protect opossum esophagus during radiotherapy. Dig Dis Sci 1982;27(10):923-928.
30. Chowhan NM. Injurious effects of radiation on the esophagus. Am J Gastroenterol 1990;(2):115-120.
31. Hughes-Davies L, Young T, Spittle M. Radiosensitivity in AIDS patients. Lancet 1991;337(8757):1616.
32. Vallis KA. Glutathione deficiency and radiosensitivity in AIDS patients. Lancet 1991;337(8746):918-919.
33. Floersheim GL. Radioprotective effects of calcium antagonists used alone or with other types of radioprotectors. Radiat Res 1993;133(1):80-87.
34. Epperly MW, Bray JA, Kraeger S, Zwacka R, Engelhardt J, Travis E, Greenberger JS. Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther 1998;5:196-208.
35. Epperly MW, Bray JA, Krager S, Berry LA, Gooding W, Engelhardt JF, Zwacka R, Travis EL, Greenberger JS. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int J Radiat Oncol Biol Phys 1999;43(1):169-181.
36. Wong GH, Elwell JH, Oberley LW, Goeddel DV. Manganese superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989;58:923-931.
37. Belani CP. Incorporation of paclitaxel and carboplatin in combined modality therapy for locally advanced nonsmall-cell lung cancer. Semin Oncol 1999;26(Suppl 2):44-54.
38. Robbins S, Cotran R, Kumar V. Robbins pathologic basis of disease, vol. 4. Philadelphia: W.B. Saunders; 1989. p 17.
39. Epperly MW, Bray JA, Esocobar P, Bigbee WL, Watkins S, Greenberger JS. Overexpression of the human MnSOD transgene in the murine hematopoietic progenitor cell line 32D cl 3 blocks apoptosis and DNA strand breaks after irradiation. Int J Radiat Oncol Biol Phys (in press).
40. Epperly MW, Bray J, Bash S, Berry L, Greenberger JS. Human MnSOD transgene expression in 32D cl 3 murine hematopoietic progenitor cells protects against irradiation apoptosis through decreased caspase 3 and PARP activation (abstract). 40TH Annual Meeting of ASH, Miami Beach, FL, December 4-8, 1998. Blood 1998;92(Suppl 1):197A, 802.